

OXCARBAZEPINE (TRILEPTAL®)

INDICATIONS

- 1) Bipolar disorder and other cyclic mood disorders

PRECAUTIONS TO CONSIDER

Contraindications

Absolute:

- 1) History of anaphylactic reaction or similarly severe significant hypersensitivity to carbamazepine or oxcarbazepine

Relative:

- 1) Hyponatremia
- 2) Severe bone marrow suppression
- 3) HLA-B*1502 allele
- 4) Severe renal impairment
- 5) Severe hepatic impairment

Precautions

- 1) Mild to moderate renal insufficiency
- 2) Mild to moderate hepatic insufficiency
- 3) Pregnancy/lactation

Pregnancy and Breast-Feeding

See relative contraindications. FDA Pregnancy Category C. Lactation Risk L3.

Drug Interactions of Major Significance

- 1) Oral estrogen and progestin products
- 2) Phenytoin, carbamazepine, phenobarbital, primidone
- 3) Antipsychotics metabolized by 3A4 (aripiprazole, quetiapine, lurasidone, clozapine, haloperidol)
- 4) Clarithromycin, fentanyl, guanfacine, itraconazole, cyclosporine,
- 5) Antidepressants metabolized by 3A4 (vilazodone, vortioxetine, MAO Inhibitors)
- 6) Apixaban, rivaroxaban
- 7) HIV medications: integrase inhibitors, maraviroc (Selzentry®), cobicistat
- 8) Antigliptin medications: linagliptin (Tradjenta®), saxagliptin (Onglyza®)

Age-Specific considerations

Geriatric population maybe more sensitive to hyponatremia.

Side Effects Which Require Medical Attention

- 1) Psychomotor retardation
- 2) Concentration difficulties
- 3) Somnolence and fatigue
- 4) Ataxia, gait disturbances
- 5) Nausea, vomiting
- 6) Signs and symptoms of hyponatremia
- 7) Rash
- 8) Fever
- 9) Suicidal ideation

PATIENT MONITORING

Patient Monitoring Parameters

- 1) CBC with differential – baseline and 1 to 2 weeks after each dose increase, annually, and as clinically indicated
- 2) Electrolytes – baseline and 1 to 2 weeks after each dose increase, annually, and as clinically indicated
- 3) Hepatic function - baseline and annually
- 4) Pregnancy Test – baseline as appropriate and as clinically indicated
- 5) For patients with Asian descent, genetic test for HLA-B*1502 at baseline (prior to the initiation of oxcarbazepine). May use results of previously completed testing.
- 6) Monitor for the emergence of suicidal ideation or behavior

Dosing

- 1) See DSHS/DADS Formulary for dosage guidelines.
- 2) Exceptions to maximum dosage must be justified as per medication rule.